Endothelial dysfunction in metabolic and vascular disorders

Postgraduate Medicine

Volumn 126, Issue 2, 2014, Pages 38-53

  Polovina, Marija M ^a   Potpara, Tatjana S ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Diabetes mellitus; Endothelial dysfunction; Flow mediated dilatation; Insulin resistance; Peripheral artery disease; Statins

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ANTICOAGULANT AGENT; AUTACOID; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED RELAXING FACTOR; FATTY ACID; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; THROMBOXANE A2; THROMBOXANE SYNTHASE; TRIACYLGLYCEROL; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASOCONSTRICTOR AGENT;

ATHEROSCLEROSIS; CELL FUNCTION; CELL SURVIVAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; GENETIC POLYMORPHISM; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; KIDNEY CIRCULATION; LIPOTOXICITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHORYLATION; REVIEW; RISK FACTOR; SHEAR STRESS; THROMBOSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; PROGNOSIS;

EID: 84900563848     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.03.2739     Document Type: Review

References (197)

1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115(10): 1285-1295.
2. Lahoz C, Mostaza JM. Atherosclerosis as a systemic disease. Rev Esp Cardiol. 2007; 60(2): 184-195.
3. Nicolls MR, Haskins K, Flores SC. Oxidant stress, immune dysregulation, and vascular function in type I diabetes. Antioxid Redox Signal. 2007; 9(7): 879-899.
4. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulindependent diabetes mellitus. Circulation. 1993; 88(6): 2510-2516.
5. Gupta AK, Ravussin E, Johannsen DL, Stull AJ, Cefalu WT, Johnson WD. Endothelial dysfunction: an early cardiovascular risk marker in asymptomatic obese individuals with prediabetes. Br J Med Med Res. 2012; 2(3): 413-423.
6. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation. 2005; 112(1): 32-38.
7. Hamburg NM, Larson MG, Vita JA, et al. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol. 2008; 101(1): 82-88.
8. Badimon L, Martínez-González J, Llorente-Cortés V, Rodríguez C, Padró T. Cell biology and lipoproteins in atherosclerosis. Curr Mol Med. 2006; 6(5): 439-456.
9. Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol (Oxf). 2013; 78(3): 438-446.
10. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide. 2013; 32: 36-42.
11. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004; 94(7): 932-935.
12. Wu HD, Berglund L, Dimayuga C, et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol. 2004; 43(10): 1828-1833.
13. Schachinger V, Halle M, Minners J, Berg A, Zeiher AM. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol. 1997; 30(4): 927-934.
14. Bogdanski P, Miller-Kasprzak E, Pupek-Musialik D, et al. Plasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial progenitor cells in patients with newly diagnosed hypertension. Clin Chem Lab Med. 2012; 50(6): 1107-1113.
15. Kim CS, Kim YR, Naqvi A, et al. Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66 shc. Cardiovasc Res. 2011; 92(3): 466-475.
16. Türemen EE, Çetinarslan B, Şahin T, Cantürk Z, Tarkun İ. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J. 2011; 58(5): 349-354.
17. Napoli R, Guardasole V, Zarra E, et al. Impaired endothelial- and nonendothelial-mediated vasodilation in patients with acute or chronic hypothyroidism. Clin Endocrinol (Oxf). 2010; 72(1): 107-111.
18. Chandran DS, Jaryal AK, Jyotsna VP, Deepak KK. Impaired endothelium mediated vascular reactivity in endogenous Cushing's syndrome. Endocr J. 2011; 58(9): 789-799.
19. Wu VC, Lo SC, Chen YL, et al; TAIPAI Study Group. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab. 2011; 96(10): 3175-3183.
20. Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest. 2012; 92(1): 1428-1439.
21. Thakur ML, Sharma S, Kumar A, et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012; 223(2): 507-511.
22. Berzigotti A, Erice E, Gilabert R, et al. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol. 2013; 108(1): 75-82.
23. Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease- a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis. 2011; 216(2): 446-451.
24. Banerjee D, Recio-Mayoral A, Chitalia N, Kaski JC. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients. Clin Cardiol. 2011; 34(6): 360-365.
25. Beckman JA, Creager MA, Libbiy P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287(19): 2570-2581.
26. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288(5789): 373-376.
27. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilatator. Hypertension. 1988; 12(4): 365-372.
28. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012; 33(7): 829-837.
29. Klatt P, Pfeiffer S, List BM, et al. Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin. J Biol Chem. 1996; 271(13): 7336-7342.
30. Abu-Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci USA. 1993; 90(22): 10769-10772.
31. Pritchard KA Jr, Ackerman AW, Gross ER, et al. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem. 2001; 276(21): 17621-17624.
32. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002; 64: 749-774.
33. Lam CF, Peterson TE, Richardson DM, et al. Increased blood flow causes coordinated upregulation of arterial eNOS and biosynthesis of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol. 2006; 290(2): H786-H793.
34. Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996; 79(5): 984-991.
35. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature. 1983; 306(5949): 174-176.
36. Förstermann U, Mülsch A, Böhme E, Busse R. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res. 1986; 58(4): 531-538.
37. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002; 23(2): 374-380.
38. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol. 2001; 280(6): H2470-H2477.
39. Saye JA, Singer HA, Peach MJ. Role of endothelium in conversion of angiotensin I to angiotensin II in rabbit aorta. Hypertension. 1984; 6(2 Pt 1): 216-221.
40. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001; 104(1): 1114-1118.
41. Nystrom FH, Quon MJ. Insulin signalling: Metabolic pathways and mechanisms for specificity. Cell Signal. 1999; 11(8): 563-574.
42. Ver MR CH, Quon MJ. Insulin signaling pathways regulating translocation of glut4. Curr Med Chem Immun Endo Metab Agents. 2005; 5: 159-165.
43. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23(2): 168-175.
44. Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol. 2005; 289(2): H813-H822.
45. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 2002; 277(3): 1794-1799.
46. Kelly LK, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol. 2004; 286(5): L984-L991.
47. Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am. 2008; 37(3): 685-711.
48. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behaviour. J Am Coll Cardiol. 2007; 49(25): 2379-2393.
49. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998; 101(11): 2567-2578.
50. Dimmeler S, Zeiher AM. Nitric oxide-an endothelial cell survival factor. Cell Death Differ. 1999; 6(10): 964-968.
51. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA. 2006; 103(39): 14537-14541.
52. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004; 110(14): 1933-1939.
53. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009; 120(13): 1266-1286.
54. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992; 326(4): 310-318.
55. Le Gouill E, Jimenez M, Binnert C, et al. Endothelial nitric oxide synthase (eNOS) knockout mice have defective mitochondrial betaoxidation. Diabetes. 2007; 56(11): 2690-2696.
56. Duplain H, Burcelin R, Sartori C, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104(3): 342-345.
57. Monti LD, Barlassina C, Citterio L, et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes. 2003; 52(5): 1270-1275.
58. Miranda JA, Belo VA, Souza-Costa DC, Lanna CM, Tanus-Santos JE. eNOS polymorphism associated with metabolic syndrome in children and adolescents. Mol Cell Biochem. 2013; 372(1-2): 155-160.
59. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004; 291(16): 1978-1986.
60. Meigs JB, O'Donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006; 55(2): 530-537.
61. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640-1645.
62. Kahn R. Metabolic syndrome-what is the clinical usefulness. Lancet. 2008; 371(9628): 1892-1893.
63. Vykoukal D, Davies MG. Vascular biology of metabolic syndrome. J Vasc Surg. 2011; 54(3): 819-831.
64. Drexler AJ, Nesto RW, Abrahamson MJ, et al. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3(2): 147-173.
65. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010; 11(1): 61-74.
66. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the pi 3-kinase- and map kinase-mediated signaling in human muscle. J Clin Invest. 2000; 105(3): 311-320.
67. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999; 104(4): 447-457.
68. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003; 20(4): 255-268.
69. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the akt site. J Clin Invest. 2001; 108(9): 1341-1348.
70. Maloney E, Sweet IR, Hockenbery DM, et al. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 2009; 29(9): 1370-1375.
71. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors: a new trend? Circulation. 1996; 94(3): 240-243.
72. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond). 2011; 121(2): 43-55.
73. Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr. 2012; 23(4): 222-231.
74. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002; 109(6): 817-826.
75. Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol. 2005; 25(8): 1551-1557.
76. Dong F, Zhang X, Li SY, et al. Possible involvement of NADPH oxidase and JNK in homocysteine-induced oxidative stress and apoptosis in human umbilical vein endothelial cells. Cardiovasc Toxicol. 2005; 5(1): 9-20.
77. Recchioni R, Marcheselli F, Moroni F, Pieri C. Apoptosis in human aortic endothelial cells induced by hyperglycemic condition involves mitochondrial depolarization and is prevented by N-acetyl-L-cysteine. Metabolism. 2002; 51(11): 1384-1388.
78. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102(1): 42-47.
79. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden TJ. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. Clin Endocrinol Metab. 1998; 83(8): 2907-2910.
80. Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A. Chemokineand cytokine-induced expression of endothelin 1 and endothelinconverting enzyme 1 in endothelial cells. J Allergy Clin Immunol. 2000; 105(2 Pt 1): 333-338.
81. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116(7): 1793-1801.
82. Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med. 1994; 179(2): 503-512.
83. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004; 279(17): 17070-17078.
84. Xu B, Chibber R, Ruggerio D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003; 17(15): 1289-1291.
85. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albuminderived advanced glycosylation end products. Circ Res. 2000; 86(3): E50-E54.
86. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation end-products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia. 1989; 41(12): 1435-1441.
87. Quehenberger P, Bierhaus A, Fasching P, et al. Endothelin 1 transcription is controlled by nuclear factor-iB in AGE-stimulated cultured endothelial cells. Diabetes. 2000; 49(9): 1561-1570.
88. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med. 2007; 120(9 Suppl 1): S10-S17.
89. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005; 29(11): 1308-1314.
90. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005; 25(5): 989-994.
91. Wang XL, Zhang L, Youker K, et al. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting akt kinase. Diabetes 2006; 55(8): 2301-2310.
92. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995; 15(7): 963-971.
93. Kawakami A, Yoshida MJ. Apolipoprotein CIII links dyslipidemia with atherosclerosis. Atheroscler Thromb. 2009; 16(1): 6-11.
94. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997; 272(34): 20963-20966.
95. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998; 98(15): 1487-1494.
96. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta J. Statins modulate oxidized low-density lipoprotein mediated adhesion molecule expression in human coronary artery endothelial cells: a role of LOXL1. J Pharmacol Exp Ther. 2002; 302(2): 601-605.
97. Verhoye E, Langlois MR; Asklepios Investigators. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med. 2009; 47(2): 128-137.
98. Ma FX, Zhou B, Chen Z, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res. 2006; 47(6): 1227-1237.
99. Mehta J. Oxidized or native low density lipoprotein cholesterol. J Am Coll Cardiol. 2006; 48(5): 988-989.
100. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003; 278(45): 45021-45026.
101. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004; 315(2): 264-271.
102. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5): H2031-H2041.
103. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003; 88(7): 3236-3240.
104. Lam TY, Seto SW, Lau YM, et al. Impairment of the vascular relaxation and differential expression of caveolin-1 of the aorta of diabetic adb//db mice. Eur J Pharmacol. 2006; 546(1-3): 134-141.
105. Bucci M, Roviezzo F, Brancaleone V, et al. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler Thromb Vasc Biol. 2004; 24(4): 721-726.
106. Das EN, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007; 55(6): 498-510.
107. Lei H, Venkatakrishnan A, Yu S, Kazlauskas A. Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitricoxide synthase activity in high glucose and diabetes. J Biol Chem. 2007; 282(13): 9364-9371.
108. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59(4): 824-833.
109. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension. 2002; 39(2): 303-307.
110. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003; 299(5608): 896-899.
111. Nisoli E, Falcone S, Tonello C, et al. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci USA. 2004; 101(47): 16507-16512.
112. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005; 307(5708): 384-387.
113. Leeper NJ, Kullo IJ, Cooke JP. Genetics of peripheral artery disease. Circulation. 2012; 125(25): 3220-3228.
114. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb. 2013; 20(1): 1-8.
115. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340(8828): 1111-1115.
116. Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009; 19(1): 6-11.
117. Ghiadoni L, Versari D, Giannarelli C, Faita F, Taddei S. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des. 2008; 14(35): 3715-3722.
118. Landim MB, Casella Filho A, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo). 2009; 64(5): 471-478.
119. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol. 2006; 98(11 A): 9P-17P.
120. Boos CJ, Blann AD, Lip GY. Assessment of endothelial damage/ dysfunction: a focus on circulating endothelial cells. Methods Mol Med. 2007; 139: 211-224.
121. Boos CJ, Balakrishnan B, Lip GY. The effects of exercise stress testing on soluble E-selectin, von Willebrand factor, and circulating endothelial cells as indices of endothelial damage/dysfunction. Ann Med. 2008; 40(1): 66-73.
122. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2): 257-265.
123. Berry KL, Skyrme-Jones RAP, Meredith IT. Occlusion cuff position is an important determinant of the time course and magnitude of human brachial artery flow-mediated dilation. Clin Sci. 2000; 99(4): 261-267.
124. Betik AC, Luckham VB, Hughson RL. Flow-mediated dilation in human brachial artery after different circulatory occlusion conditions. Am J Physiol Heart Circ Physiol. 2004; 286(1): H442-H448.
125. Bressler B, Chan S, Mancini GBJ. Temporal response of brachial artery dilation after occlusion and nitroglycerin. Am J Cardiol. 2002; 85(3): 391-394.
126. Polovina M, Potpara T, Giga V, Ostojić M. Significance of heterogeneity in endothelium-dependent vasodilatation occurrence in healthy individuals with or without coronary risk factors. Vojnosanit Pregl. 2009; 66(10): 813-820.
127. Parker BA, Ridout SJ, Proctor DN. Age and flow-mediated dilation: a comparison of dilatory responsiveness in the brachial and popliteal arteries. Am J Physiol Heart Circ Physiol. 2006; 291(6): H3043-H3049.
128. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res. 2008; 122(1): 85-90.
129. Polovina M, Potpara T, Giga V, Stepanovic J, Ostojic MC. Impaired endothelial function in lone atrial fibrillation. Vojnosanit Pregl. 2013; 70(10): 9082914.
130. Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil. 2011; 18(6): 775-789.
131. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011; 300(1): H2-H12.
132. Woodman RJ, Playford DA, Watts GF, et al. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol. 2001; 91(2): 929-937.
133. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow- mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998; 82(12): 1535-1539, A7-A8.
134. Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis. 2003; 14(5): 425-431.
135. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003; 38(2): 374-379.
136. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004; 110(13): 1794-1798.
137. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986; 315(17): 1046-1051.
138. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989; 80(3): 458-465.
139. Corretti MC, Anderson TJ, Benjamin EJ, et al; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2): 257-265.
140. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995; 91(5): 1314-1319.
141. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients , 40 years of age with coronary artery disease. Am J Cardiol. 1996; 78(11): 1210-1214.
142. Neunteufl T, Heher S, Katzenschlager R, Wölfl G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol. 2000; 86(2): 207-210.
143. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009; 53(4): 323-330.
144. Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol. 2006; 98(11): 1424-1428.
145. Akcakoyun M, Kargin R, Tanalp AC, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study. Coron Artery Dis. 2008; 19(5): 337-343.
146. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101(9): 948-954.
147. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101(16): 1899-1906.
148. Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis. 1999; 10(6): 375-380.
149. Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation. 2005; 111(1): 70-75.
150. Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis. 2008; 197(1): 1-11.
151. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002; 106(7): 820-825.
152. Brevetti G, De Caterina M, Martone VD, et al. Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. Clin Hemorheol Microcirc. 2001; 24(3): 193-199.
153. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003; 108(17): 2093-2098.
154. Perrone-Filardi P, Cuocolo A, Brevetti G, et al. Relation of brachial artery flow-mediated vasodilation to significant coronary artery disease in patients with peripheral arterial disease. Am J Cardiol. 2005; 96(9): 1337-1344.
155. Pellegrino T, Storto G, Filardi PP, et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. J Nucl Med. 2005; 46(12): 1997-2002.
156. Silvestro A, Brevetti G, Schiano V, Scopacasa F, Chiariello M. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost. 2005; 93(3): 559-563.
157. Gokce N, Keaney Jr JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002; 105(13): 1567-1572.
158. Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003; 41(10): 1769-1775.
159. Huang AL, Silver AE, Shvenke E, et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol. 2007; 27(10): 2113-2119.
160. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002; 40(3): 505-510.
161. Schindler TH, Hornig B, Buser PT, et al. Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol. 2003; 23(3): 495-501.
162. Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010; 121(2): 230-236.
163. Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S; JPHC Study Group. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res. 2009; 32(4): 289-298.
164. Naylor LH, Green DJ, Jones TW, et al. Endothelial function and carotid intima-medial thickness in adolescents with type 2 diabetes mellitus. J Pediatr. 2011; 159(6): 971-974.
165. Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis. 2005; 183(1): 113-120.
166. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002; 106(16): 2085-2090.
167. Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J. 2008; 156(2): 405-410.
168. Meeking DR, Cummings MH, Thorne S, et al. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. Diabet Med. 1999; 16(10): 841-847.
169. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009; 32(Suppl 2): S314-S321. doi: 10.2337/dc09-S330.
170. Laurenti O, Vingolo EM, Desideri GB, et al. Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage. Exp Clin Endocrinol Diabetes. 1997; 105(Suppl 2): 40-42.
171. Roberts CK, Barnard RJ, Jasman A, Balon TW Acute exercise increases nitric oxide synthase activity in skeletal muscle. Am J Physiol. 1999; 277(2 Pt 1): E390-E394.
172. Adams V, Linke A, Kränkel N, et al. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation. 2005; 111(5): 555-562.
173. Siasos G, Tousoulis D, Tsigkou V, et al. Flavonoids in atherosclerosis: an overview of their mechanisms of action. Curr Med Chem. 2013; 20(21): 2641-2660.
174. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002; 62(2): 265-284.
175. Sládková M, Kojsová S, Jendeková L, Pechánová O. Chronic and acute effects of different antihypertensive drugs on femoral artery relaxation of L-NAME hypertensive rats. Physiol Res. 2007; 56(Suppl 2): S85-S91.
176. Zepeda RJ, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012; 111(5): 309-316.
177. Radenković M, Stojanović M, Potpara T, Prostran M. Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art. Biomed Res Int. 2013; 2013: 252158. doi: 10.1155/2013/252158.
178. Kayaalti F, Kalay N, Basar E, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels. 2010; 25(2): 92-96.
179. Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press. 2010; 19(1): 40-47.
180. Chłopicki S, Gryglewski RJ. Angiotensin converting enzyme (ACE) and hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep. 2005; 57(Suppl): 86-96.
181. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97(12): 1129-1135.
182. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation. 2004; 110(19): 3136-3142.
183. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy-part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010; 44(4): 241-251.
184. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995; 332(8): 488-493.
185. Dahmus JD, Bruning RS, Kenney WL, Alexander LM. Oral clopidogrel improves cutaneous microvascular function through EDHF-dependent mechanisms in middle-age humans. Am J Physiol Regul Integr Comp Physiol. 2013; 305(4): R4522-R4528.
186. Potpara TS, Lip GY. Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation. Curr Pharm Des. 2010; 16(31): 3455-3471.
187. Potpara TS, Lip GY. New anticoagulation drugs for atrial fibrillation. Clin Pharmacol Ther. 2011; 90(4): 502-506.
188. Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Adv Ther. 2012; 29(6): 491-507. doi: 10.1007/ s12325-012-0026-8.
189. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003; 52(2): 173-180.
190. Forst T, Lübben G, Hohberg C, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation. 2005; 12(7): 543-550.
191. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002; 287(11): 1420-1426.
192. Ceriello A. Thiazolidinediones as anti-inflammatory and antiatherogenic agents. Diabete Metab Res Rev. 2008; 24(1): 14-26.
193. de Aguiar LG, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006; 29(5): 1083-1089.
194. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005; 258(3): 250-256.
195. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. 2003; 29 (pt 2): 6S71-6S76.
196. Chen LL, Yu F, Zeng TS, Liao YF, Li YM, Ding HC. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur J Pharmacol. 2011; 659(2-3): 296-301.
197. Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR-uuagonist in treatment of diabetes: cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem. 2012; 10(2): 124-134.